Key facts
- This page summarizes Mark E. Saad's Form 4 filing for Axsome Therapeutics, Inc. (AXSM).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 09 Jun 2026, 17:16.
Mark E. Saad - 05 Jun 2026 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)
- Reporting relationship
- Director
- Issuer ticker
- AXSM
- Reported as of
- 05 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Jun 2026, 17:16:19 UTC
- Prior SEC filing
- 02 Jan 2026
- Next SEC filing
- 10 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nick Pizzie, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark E. Saad filed Form 4 for Axsome Therapeutics, Inc. (AXSM) on 09 Jun 2026.
Change
- Previous filing in this sequence was filed on 02 Jan 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001295913
Primary reporting owner
Saad Mark E
- Relationship
- Director
- Address
- C/O AXSOME THERAPEUTICS, INC., ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
- Signature
- /s/ Nick Pizzie, Attorney-in-Fact
- Signature date
- 09 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AXSM
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- Shares
- +1,721
- Change %
- Price
- $0.000000*
- Shares after
- 1,721
- Date
- 05 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,721
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
The RSUs vest in full on the one-year anniversary of the date of grant.